Completing data — refresh the page later to see the latest
77472-98-1c1ccc(-c2cc(CCC3CCNCC3)c3ccccc3n2)cc1AMEWZCMTSIONOX-UHFFFAOYSA-NPipequaline is an anticonflict & anticonvulsant quinoline derivative. It is an anxiolytic drug that was never marketed. It presents a unique chemical structure that does not follow the structural properties of other drugs of its class. Pipequaline has a similar pharmacological profile to the reported for the benzodiazepines. However, it presents a significant set of anxiolytic properties with a very little sedative, amnestic or anticonvulsant effect. Due to these differences, this drug is classified as a nonbenzodiazepine anxiolytic.
77472-98-1Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
DescriptionPipequaline is a partial agonist of central benzodiazepine receptors (Ki = 78 nM in a radioligand binding assay). In mice, pipequaline enhances the effects of diazepam , further reducing foot shock-induced fighting behavior and the number of maximal electroshock-induced seizures and potentiating the muscle relaxant and hypnotic effects. Pipequaline also increases drinking in the Vogel punished drinking task indicating anxiolytic-like activity that can be reversed by the benzodiazepine receptor antagonist flumazenil .
UsesPipequaline (PK 8165) is a partial benzodiazepine receptor agonist with anxiolytic activity[1][2].
Loading…
DTXSID20228183CHEMBL2105206